Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2005-08-23
2005-08-23
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C534S010000, C546S193000, C546S296000, C544S131000
Reexamination Certificate
active
06932960
ABSTRACT:
N-substituted 3-hydroxy-4-pyridinones and metal chelates, methods of preparing N-substituted 3-hydroxy-4-pyridinones and metal chelates, and pharmaceutical compositions containing new N-substituted 3-hydroxy-4-pyridinones and/or their metal chelates. Use of N-substituted 3-hydroxy-4-pyridinones and their metal chelates as pharmaceutical agents for the treatment of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation.
REFERENCES:
patent: 2136807 (1938-11-01), Stoker
patent: 4908371 (1990-03-01), Moerker et al.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5256676 (1993-10-01), Hider et al.
patent: 5525326 (1996-06-01), Unger
patent: 5527790 (1996-06-01), McNeill et al.
patent: 5688815 (1997-11-01), Zbinden et al.
patent: 5716598 (1998-02-01), Golman et al.
patent: 5866563 (1999-02-01), McNeil et al.
patent: 5877210 (1999-03-01), Schieven
patent: 5980863 (1999-11-01), Harnish et al.
patent: 6046219 (2000-04-01), Hanauske-Abel et al.
patent: 6232340 (2001-05-01), Zhang et al.
patent: 6294152 (2001-09-01), Davies et al.
patent: 6323340 (2001-11-01), Masuda et al.
patent: 0 316 279 (1989-05-01), None
patent: 0 335 745 (1989-10-01), None
patent: 1 006 108 (2000-06-01), None
patent: 1 006 112 (2000-06-01), None
patent: 2 269 589 (1994-02-01), None
patent: 2 345 058 (2000-06-01), None
patent: 07 179 474 (1995-07-01), None
patent: WO 91/12822 (1991-09-01), None
patent: WO 93/10822 (1993-06-01), None
patent: WO 96/05867 (1996-02-01), None
patent: WO 96/22021 (1996-07-01), None
patent: WO 96/41639 (1996-12-01), None
patent: WO 97/02842 (1997-01-01), None
patent: WO 98/01458 (1998-01-01), None
patent: WO 98/54138 (1998-12-01), None
patent: WO 99/23075 (1999-05-01), None
patent: WO 99/30562 (1999-06-01), None
patent: WO 00/16736 (2000-03-01), None
patent: WO 00/16782 (2000-03-01), None
patent: WO 00/24730 (2000-05-01), None
patent: WO 01/12168 (2001-02-01), None
Abeysinghe, R.D., et al., “The environment of the lipoxygenase iron binding site explored with novel hydroxpyridine iron chelators,”J. of Biological Chem.,1996, 271(44), 7965-7972.
Ahmed, S.I., et al., “The structures of bis-maltolato-zinc(II) and of bis-3-hydroxy-1,2-dimethyl-4-pyridinonato-zinc(II) and-lead(II),”Polyhedron,2000, 19, 129-135.
Barret, M.C., et al., “Synthesis and structural characterization of Tin(II) and Zinc(II) derivatives of cyclic α-hydroxyketones, including the structures of Sn(mltol)2, Sn(troplone)2, Zn(troplone)2, and Zn(hinokitiol)2,”Inorg. Chem.,2001, 40, 4384-4388.
Bebbington, D., et al., “3,5-disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4-(1H)-pyridione: potent inhibitors of lipid peroxidation and cell toxicity,”J. Med. Chem.,2000, 43, 2779-2782.
Bickerdike, M.J., et al., “Enhanced acetylcholine release in striatum after chronic amphetamine is NMDA-dependent,”NeuroReport,1999, 10, 77-80.
Bosquet, J.-C., et al., “Gd-DOTA: characterization of a new paramagnetic complex,”Radiology,1988, 166, 693-698.
Branen, A. L., et al., “Use of antioxidants in self-preserving cosmetic and drug formulations,”Cosmet. Sci. Technol. Ser.,1997, 16, 159-179.
Brewer, G.J., “Cooper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's Disease,”Exp. Biol. Med.,2001, 226(7), 665-673.
CAPLUS Accession No. 1995:887972 (English abstract of Japanese Patent).
Caravan, P., et al., “Gadolinium(III) chelates as MRI constrast agents: structure, dynamics and applications,”,Chem. Rev.,1999, 99, 2293-2352.
Caravan, P., et al., “Reaction chemistry of BMOV, Bis(maltolato)oxovanadium(IV)—apotent insulin mimetic agent,”J. Am. Chem. Soc.,1995, 117, 12750-12770.
Clarke, E.T., et al., “Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions,”Inorganica Chimica Acta,1992, 191, 57-63.
Dobbin, P.S., et al., “Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential,”J. Med. Chem.,1993, 36, 2448-2458.
Dutt, N.K., et al., “Chemistry of lanthanons—XL1. isolation and characterization of tris chelates of lanthanides with maltol, kojic acid and chloro-kojic acid,”J. Inorg. Nucl. Chem.,1975, 37, 1801-1802.
Edwards, D.S., et al., “Characterization of Tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV)cations,”Inorg. Chem.,1994, 33, 5607-5609.
Edwards, D.S., et al., “Potential99mTc radiopharmaceuticals for renal imaging: tris(N-substituted-3-hydroxy-2-methyl-4-pyridinonato)technetium(IV)cations,”Nucl. Med. Biol.,1993, 20(7), 857-863.
El-Jammal, A., et al., “Cooper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies,”J. Med. Chem.,1994, 37, 461-466.
Ellis, B.L., et al., “6-alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labeling with indium,”Eur. J. Nucl. Med.,1999, 26, 1400-1406.
Ellis, B.L., et al., “Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling,”J. Med. Chem.,1996, 39, 3659-3670.
Faller, B., et al., “Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network,”J. Med. Chem.,2000, 43, 1467-1475.
Fernandez, J.A., et al., “Essential viral and cellular zinc an iron containing metalloproteins as targets for novel antiviral and anticancer agents: implications for prevention and therapy of viral diseases and cancer,”Anticancer Res.,2001, 21, 931-958.
Ferrali, M., et al., “3-hydroxy-(4H-)-benzopyran-4-ones as potential iron chelating agents in vivo,”Bioorganic&Medicinal Chem.,2001, 9, 3041-3047.
Foda, H.D., et al., “Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis,”DDT,2001, 9, 478-482.
Gutteridge, J.M.C., et al., “Iron toxicity and oxygen radicals,”Ballièr's Clin. Haematology,1989, 2(2), 195-256.
Gwyn, K., et al., “Breast cancer during pregnancy,”Oncology,2001, 15(1), 39-46.
Hashimoto, M., et al., “Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro,”NeuroReport,1999, 10, 717-721.
Henrotin, Y., et al., “The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives,”Expert Opin. Ther. Patents,2002 12(1), 29-43.
Hidalgo, M., et al., “Development of matrix metalloproteinase inhibitors in cancer therapy,”J. of the National Cancer Institute,2001, 93(3), 178-193.
Hider, R.C., et al., “Design of orally active iron chelators,”Acta Haematol,1996, 95, 6-12.
Hu, T.C.-C., et al., “Manganese-enhanced MRI of mouse heart during changes in inotropy,”Magnetic Resonance in Medicine,2001, 46, 884-890.
Hunter, D.R., et al., “Comparison of Ca2+, SR2+, and Mn2+fluxes in mitochondria of the perfused rat heart,”Circ. Res.,1980, 47, 721-727.
John A., et al., “The role of matrix metalloproteinases in tumor angiogenesis of tumor metastasis,”Pathology Oncology Res.,2001, 7(1), 14-23.
Liu, Z.D., et al., “Design, synthesis and evaluation of N-basis substituted 3-hydroxypryridin-4-ones: orally active iron chelators with lysosomotrophic potential,”J. Pharm. Pharmacol.,2000, 52, 263-272.
Liu, Z.D., et al., “Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase,”Biochem. Pharmac.,2001, 285-290.
Liu, Z.D., et al., “Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+values,”bioorganic&Medicinal Chem.,2001, 9, 563-573.
Aulakh Charanjit S.
Bristol-Myers Squibb Pharma Company
Woodcock & Washburn LLP
LandOfFree
N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498717